Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic

  • Delia Mezzanzanica
  • Silvana Canevari
  • Maria I. Colnaghi
Reviews

Summary

We have selected a monoclonal antibody (MOv18) reactive with ovarian carcinoma, which exhibits a restricted tumor specificity, a high affinity constant and which recognizes a 38-kDa glycoprotein homogeneously expressed on the cell surface of 90% of human ovarian carcinomas. Localization studies with radiolabelled MOv18 showed that MOv18 could specifically reach ovarian carcinoma cells growing in the peritoneal cavity of nu/nu mice. MOv18 did not mediate antibody-dependent cellular cytotoxicity via Fc and could not be used as a carrier for toxins due to poor internalization of the antigen-antibody complex. Bispecific F(ab′)2 antibodies made with MOv18 and an antibody reactive with CD3 were able to redirect the cytotoxicity of peripheral blood lymphocytes (PBL) against ovarian carcinoma cells both in vitro and in vivo in an animal model. The treatment of athymic mice bearing a human ovarian carcinoma intraperitoneally, with human PBL coated with the bispecific F(ab′)2, significantly prolonged survival of the animals compared with tumour-bearing untreated and control mice treated with PBL alone. Four ovarian cancer patients have been treated with autologous lymphocytes coated with this bispecific F(ab′)2 in a phase I clinical trial. No serious side-effects were observed but patients developed human anti-murine antibodies mainly directed against the idiotype of MOv18. We have now begun phase II clinical trials in ovarian cancer patients.

Key words

Ovarian carcinoma Target cellular cytotoxicity Bispecific antibody Athymic mice 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bénard J, De Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, Riou G, Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 45:4970, 1985PubMedGoogle Scholar
  2. 2.
    Brennan M, Davison PF, Paulus H, Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229: 81, 1985PubMedCrossRefGoogle Scholar
  3. 3.
    Canevari S, Ménard S, Mezzanzanica D, Miotti S, Pupa SM, Lanzavecchia A, Colnaghi MI, Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cell. Int J Cancer [Suppl] 2: 18, 1988CrossRefGoogle Scholar
  4. 4.
    Canevari S, Gogliati T, Mezzanzanica D, Orlandi R, Colnaghi MI, Anticorpi monoclonali anti carcinomi umani quali vettori di tossine. J Chemother [Suppl] 2: 370, 1990Google Scholar
  5. 5.
    Cogliati T, Brusa P, Canevari S, Caldera M, Mezzanzanica D, Dosio F, Cattel L, Colnaghi MI, Preparation and biological characterization of conjugates consisting of ricin and a tumor-specific non-internalizing Mab. Anticancer Res 11: 417, 1991PubMedGoogle Scholar
  6. 6.
    Colnaghi MI, Canevari S, Conde F, Leoni F, Ménard S, Orlandi R, Pizzetti P, Porro G, Ripamonti M, Monoclonal antibodies: perspectives for tumor therapy. In: Gallo RC, Della Porta G, Albertini A (eds) Monoclonals and DNA probes in diagnostic and preventive medicine. Raven, New York, pp 137–146, 1987Google Scholar
  7. 7.
    Colnaghi MI, Canevari S, Ménard S, Monoclonal antibodies in immunodiagnosis and immunotherapy of human cancer. Eur J Surg Oncol 14: 1, 1988PubMedGoogle Scholar
  8. 8.
    Colnaghi MI, Buraggi GL, Canevari S, Di Re F, Leoni F, Mangioni C, Ménard S, Orlandi R, Evaluation of the suitability of a monoclonal antibody raised against human ovarian carcinoma for therapeutic approaches. Nucl Med Biol 16: 633, 1989Google Scholar
  9. 9.
    Crippa F, Buraggi GL, Di Re E, Gasparini M, Seregni E Canevari S, Gadina M, Presti M, Marini A, Seccamani E, Radioimmunoscintigraphy with131I-MOv18 administrated by intraperitoneal and intravenous routes in ovarian cancer patients. Eur J Cancer 27: 724, 1991PubMedCrossRefGoogle Scholar
  10. 10.
    Fanger MW, Graziano RF, Shen, L, Guyre PM, FcγR cytotoxicity exerted by mononuclear cells. Chem Immunol 47: 214, 1989PubMedCrossRefGoogle Scholar
  11. 11.
    Foon KA, Biological response modifiers: the new immunotherapy. Cancer Res 49: 1621, 1989PubMedGoogle Scholar
  12. 12.
    Gadina M, Canevari S, Ripamonti M, Mariani M, Colnaghi MI, Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MOv18. Nucl Med Biol 18: 403, 1991Google Scholar
  13. 13.
    Garrido MA, Perez P, Titus JA, Valdayo MJ, Winkler DF, Barbieri SA, Wunderlich JR, Segal DM, Targeted cytotoxic cells in human peripheral blood lymphocytes. J Immunol 144: 2891, 1990PubMedGoogle Scholar
  14. 14.
    Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, Wunderlich JR, Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice. Cancer Res 50: 4227, 1990PubMedGoogle Scholar
  15. 15.
    Glennie MJ, McBride HM, Worth AT, Stevenson GT, Preparation and performance of bispecific F(ab′)2 antibody containing thioether-linked Fab' fragments. J Immunol 139: 2367, 1987PubMedGoogle Scholar
  16. 16.
    Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, Ozol RF, Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 44: 5286, 1984PubMedGoogle Scholar
  17. 17.
    Jung G, Honsik CJ, Reisfeld RA, Muller-Eberhard HJ, Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target anti-T3 conjugates. Proc Natl Acad Sci USA 83:4479, 1986PubMedCrossRefGoogle Scholar
  18. 18.
    Karpovsky B, Titus JA, Stephany DA, Segal DM, Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fcγ receptor antibodies. J Exp Med 160: 1686, 1984PubMedCrossRefGoogle Scholar
  19. 19.
    Lanzavecchia A, Scheidegger D, The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 17: 105, 1987PubMedCrossRefGoogle Scholar
  20. 20.
    Liu MA, Kranz DM, Kurnick JT, Boyle LA, Levy R, Eisen HN, Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 8648, 1985PubMedCrossRefGoogle Scholar
  21. 21.
    Menard S, Rilke F, Della Porta G, Mariani-Costantini R, Regazzoni M, Tagliabue E, Alasio L, Colnaghi MI, Sensitivity enhancement of the cytologic detection of cancer cells in effusion by monoclonal antibodies. Am J Clin Pathol 83: 571, 1985PubMedGoogle Scholar
  22. 22.
    Mezzanzanica D, On behalf of the International Group for Ovarian Carcinoma Therapy, Human PBL retargeting by bispecific antibodies: preclinical data and phase I clinical trial. J Cell Biochem [Suppl] 15E: 137, 1991Google Scholar
  23. 23.
    Mezzanzanica D, Canevari S, Ménard S, Pupa SM, Tagliabue E, Lanzavecchia A, Colnaghi MI, Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer 41: 609, 1988PubMedCrossRefGoogle Scholar
  24. 24.
    Mezzanzanica D, Canevari S, Casalini P, Della Torre G, Colnaghi MI, Monoclonal antibodies in cancer therapy: selection of the most appropriate reagent for different approaches. In: Metzgar R, Mitchell M (eds) Human tumor antigens and specific tumor therapy, Liss, New York, p 181–190, 1989Google Scholar
  25. 25.
    Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR Jr, Segal DM, Wunderlich JR, Human T lymphocytes targeted against human ovarian carcinoma with bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res, in press, 1991Google Scholar
  26. 26.
    Milstein C, Cuello AC, Hybrid hybridomas and the production of bi-specific monoclonal antibodies. Immunol Today 5: 299, 1984CrossRefGoogle Scholar
  27. 27.
    Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E, Colnaghi MI, Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39: 297, 1987PubMedCrossRefGoogle Scholar
  28. 28.
    Nitta T, Sato K, Yagita H, Okumura K, Ishii S, Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368, 1990PubMedCrossRefGoogle Scholar
  29. 29.
    Pastan I, Willingham MC, FitzGerald DJ, Immunotoxins. Cell 47: 641, 1986PubMedCrossRefGoogle Scholar
  30. 30.
    Perez P, Hoffman RW, Show S, Bluestone JA, Segal DM, Specific targeting of cytotoxic T cells by anti-T3 linked to antitarget cell antibody. Nature 316: 354, 1985PubMedCrossRefGoogle Scholar
  31. 31.
    Perez P, Hoffman RW, Titus JA, Segal DM, Specific targeting of human peripheral blood T cells by heteroconjugates containing anti-T3 crosslinked to anti-target cell antibodies. J Exp Med 163: 166, 1986PubMedCrossRefGoogle Scholar
  32. 32.
    Pupa SM, Canevari S, Fontanelli R, Menard S, Mezzanzanica D, Lanzavecchia A, Colnaghi MI, Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. Int J Cancer 42: 455, 1988PubMedCrossRefGoogle Scholar
  33. 33.
    Pupa SM, Canevari S, Colzani E, Damgard EM, Menard S, Miotti S, Colnaghi MI, Purification of bispecific monoclonal antibodies produced by a hybrid hybridoma. J Immunol Res 3: 16, 1991Google Scholar
  34. 34.
    Roosnek E, Lanzavecchia A, Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell. J Exp Med 170: 297, 1989PubMedCrossRefGoogle Scholar
  35. 35.
    Segal DM, Snider DP, Targeting and activation of cytotoxic lymphocytes. Chem Immunol 47: 179, 1989PubMedCrossRefGoogle Scholar
  36. 36.
    Segal DM, Wunderlich JR, Targeting of cytotoxic cells with heterocrosslinked antibodies. Cancer Invest 6: 83, 1988PubMedCrossRefGoogle Scholar
  37. 37.
    Shawler DL, Bartholomew RM, Smith LM, Dillman RO, Human immune response to multiple injection of murine monoclonal IgG. J Immunol 135: 1530, 1985PubMedGoogle Scholar
  38. 38.
    Staerz UD, Kanagawa O, Bevan MJ, Hybrid antibodies can target sites for attack by T cells. Nature 314: 628, 1985PubMedCrossRefGoogle Scholar
  39. 39.
    Titus JA, Garrido MA, Hecht TT, Winkler DF, Wunderlich JR, Segal DM, Human T cells targeted with anti-T3 crosslinked to anti-tumor antibody prevent tumor growth in nude mice. J Immunol 138: 4018, 1987PubMedGoogle Scholar
  40. 40.
    Titus JA, Perez P, Kaubish A, Garrido MA, Segal DM, Human K/natural killer cells targeted with heterocrosslinked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol 139: 3153, 1987PubMedGoogle Scholar
  41. 41.
    Tondini C, Pap SA, Hayes DF, Elias AD, Kufe DW, Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res 50: 1170, 1990PubMedGoogle Scholar
  42. 42.
    Young RC, Knapp RC, Perez CA, Cancer of the ovary. In: De Vita VTJ, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. Lippincott, Philadelphia, p 884, 1982Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Delia Mezzanzanica
    • 1
  • Silvana Canevari
    • 1
  • Maria I. Colnaghi
    • 1
  1. 1.Division of Experimental Oncology EIstituto Nazionale TumoriMilanItaly

Personalised recommendations